Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma

Autor: Ryo Takagi, Tsutomu Kobayashi, Shin-ichi Fuchida, Kazuho Shimura, Nobuhiko Uoshima, Hiroto Kaneko, Junya Kuroda, Yuji Shimura, Taku Tsukamoto, Katsuya Wada, Masafumi Taniwaki, Mitsushige Nakao, Miki Kiyota, Kazuna Tanba, Chihiro Shimazaki, Isao Yokota, Shigeo Horiike, Yutaka Kobayashi, Hitoji Uchiyama, Yoshiaki Chinen
Rok vydání: 2020
Předmět:
Zdroj: Leukemia & Lymphoma. 61:3378-3386
ISSN: 1029-2403
1042-8194
Popis: Extended post-therapy long-term survival of patients with diffuse large B cell lymphoma (DLBCL) may also lead to an increase of late adverse events. We retrospectively investigated the frequency and clinical manifestation of second primary malignancy (SPM) after rituximab-containing immunochemotherapy in patients with DLBCL treated at seven institutes belonging to the Kyoto Clinical Hematology Study Group (KOTOSG) from the perspective of the existence of past or synchronous cancer history. In a median follow-up period of 899 days, 69 SPMs were observed in 58 of 809 patients. The most frequent SPM was gastric cancer, followed by lung cancer and colorectal cancer. The cumulative incidence of SPM increased steadily over time and was not significantly influenced by the presence or absence of past or synchronous cancer history. Our study suggests the need for careful attention to SPM in patients with DLBCL in daily practice.
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje